WO2018062122A1 - Composition pour favoriser la sécrétion de peptides natriurétiques atriaux - Google Patents

Composition pour favoriser la sécrétion de peptides natriurétiques atriaux Download PDF

Info

Publication number
WO2018062122A1
WO2018062122A1 PCT/JP2017/034617 JP2017034617W WO2018062122A1 WO 2018062122 A1 WO2018062122 A1 WO 2018062122A1 JP 2017034617 W JP2017034617 W JP 2017034617W WO 2018062122 A1 WO2018062122 A1 WO 2018062122A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
natriuretic peptide
atrial natriuretic
secretion
compound
Prior art date
Application number
PCT/JP2017/034617
Other languages
English (en)
Japanese (ja)
Inventor
信悟 細尾
平田　哲也
浩蔵 中村
Original Assignee
小林製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 小林製薬株式会社 filed Critical 小林製薬株式会社
Publication of WO2018062122A1 publication Critical patent/WO2018062122A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • Test example (1) Preparation of geniposide acid (GEA) Sodium hydroxide was added to purified water to a concentration of 48% by weight and the temperature was raised to 50 ° C. Geniposide (purchased from Sichuan Twins Biological Technology Co., Ltd.) was added over 6 minutes and stirred at 50 ° C. for 2 hours. After confirming the disappearance of the raw materials by visual observation, it was cooled to around 25 ° C. and neutralized with 4N hydrochloric acid to obtain a crude geniposide acid solution.
  • GAA geniposide acid
  • the crude geniposide acid solution was adjusted to pH 3.5 with dilute hydrochloric acid and adsorbed on ODS (Daisogel SP-120-40 / 60 ODS-B, manufactured by Daiso Corporation) equilibrated with water. Subsequently, it was washed with purified water for desalting and eluted with 50% by volume methanol aqueous solution to obtain highly pure geniposide acid (purity 99.5% or more).
  • the calibration curve was created with the natural logarithm of the standard solution concentration on the horizontal axis and the natural logarithm of the measured value on the vertical axis.
  • the coefficient of determination R 2 of the obtained straight line was 0.9984, and there was no problem with linearity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Le problème décrit par la présente invention est de fournir une nouvelle composition qui est capable de favoriser la sécrétion d'un peptide natriurétique atrial. La solution selon l'invention porte sur une composition pour favoriser la sécrétion d'un peptide natriurétique atrial, ladite composition comprenant un composé ayant un squelette (chaîne principale) iridoïde.
PCT/JP2017/034617 2016-09-28 2017-09-26 Composition pour favoriser la sécrétion de peptides natriurétiques atriaux WO2018062122A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016189715A JP6818486B2 (ja) 2016-09-28 2016-09-28 心房性ナトリウム利尿ペプチド分泌促進用組成物
JP2016-189715 2016-09-28

Publications (1)

Publication Number Publication Date
WO2018062122A1 true WO2018062122A1 (fr) 2018-04-05

Family

ID=61760629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/034617 WO2018062122A1 (fr) 2016-09-28 2017-09-26 Composition pour favoriser la sécrétion de peptides natriurétiques atriaux

Country Status (3)

Country Link
JP (1) JP6818486B2 (fr)
TW (1) TWI747945B (fr)
WO (1) WO2018062122A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023288283A2 (fr) 2021-07-14 2023-01-19 Synthekine, Inc. Méthodes et compositions destinées à être utilisées dans la thérapie cellulaire contre la maladie néoplasique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010408A1 (fr) * 1994-09-30 1996-04-11 The Executive Director Of The Western Australian Department Of Conservation And Land Management Composes agissant sur le coeur, isoles des plantes ligneuses vivaces

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6789613B2 (ja) * 2015-02-25 2020-11-25 小林製薬株式会社 経口組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010408A1 (fr) * 1994-09-30 1996-04-11 The Executive Director Of The Western Australian Department Of Conservation And Land Management Composes agissant sur le coeur, isoles des plantes ligneuses vivaces

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIRATA, TETSUYA ET AL.: "4. Mechanism of action on blood pressure of Eucommia leaf glycoside", BENEFICIAL EFFECTS OF EUCOMMIA LEAF ON VASCULAR ENDOTHELIAL FUNCTION AND ANTI-OBESITY, THE CELL, vol. 48, no. 10, 20 September 2016 (2016-09-20), pages 507 - 512 *
XU D.Y. ET AL.: "K^+"A"C"h channel activation with carbachol increases atrial ANP release", LIFE SCIENCES, vol. 82, no. 21-22, 29 March 2008 (2008-03-29), pages 1083 - 1091, XP022648480 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023288283A2 (fr) 2021-07-14 2023-01-19 Synthekine, Inc. Méthodes et compositions destinées à être utilisées dans la thérapie cellulaire contre la maladie néoplasique

Also Published As

Publication number Publication date
JP2018052846A (ja) 2018-04-05
TWI747945B (zh) 2021-12-01
JP6818486B2 (ja) 2021-01-20
TW201813647A (zh) 2018-04-16

Similar Documents

Publication Publication Date Title
Hayakawa et al. Effect of a γ-aminobutyric acid-enriched dairy product on the blood pressure of spontaneously hypertensive and normotensive Wistar–Kyoto rats
KR101561717B1 (ko) 인간의 근육 생리에 영향을 미치는 25-하이드록시-비타민 ｄ3의 용도
Benedict et al. The origin of urinary creatine in progressive muscular dystrophy
Brun et al. Luminal calcium concentration controls intestinal calcium absorption by modification of intestinal alkaline phosphatase activity
CS197387B1 (en) Pharmaceutical mixture for decreasing the cholesterole level in the blood
EP1964566A1 (fr) Preparation ayant une capacite de bioabsorption amelioree de sapropterine chlorhydrate
US20240228426A1 (en) Dicarboxylic acid diesters
PT1446112E (pt) Utilização de glutamato, derivados ou metabolitos de glutamato, análogos de glutamato ou misturas dos mesmos para o fabrico de uma composição para o tratamento da osteoporose
WO2018062122A1 (fr) Composition pour favoriser la sécrétion de peptides natriurétiques atriaux
DE69902127T2 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
WO2007026820A1 (fr) Utilisation de l'effet anti-hypertensif/hypercardie du d-allose
WO2015085351A1 (fr) Composition de pharmaconutriments
Chen et al. Absorption characteristics of novel compound calcium carbonate granules: effects of gastric acid deficiency and exogenous weak acids
US20060229243A1 (en) Aequorin-containing compositions and methods of using same
WO2003097081A1 (fr) Composition pour traiter ou prevenir une hyperuricemie
WO2013073698A1 (fr) Peptide inhibiteur de l'activité de cxcr4 et son application
KR102276379B1 (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물
AU2004281559B2 (en) Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)
JP6145352B2 (ja) 納豆菌を用いたマコンブ発酵物の血圧上昇抑制剤
JP3248170B2 (ja) コンドロイチン硫酸蛋白複合体含有食品
JP6145353B2 (ja) Ｌａｃｔｏｂａｃｉｌｌｕｓ属を用いた発酵ヒダカコンブの血圧上昇抑制剤
JPS58501120A (ja) 生物学的活性ペプチド
US20110098216A1 (en) Therapeutic uses of colostrinin
US9526717B2 (en) Composition for treating immune diseases containing daurinol compound as active ingredient
WO2022191184A1 (fr) Agent d'amélioration de la sensibilité du récepteur de ghréline, composition d'amélioration de la sensibilité du récepteur de ghréline et procédé d'activation du récepteur de ghréline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17856073

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17856073

Country of ref document: EP

Kind code of ref document: A1